Measure #140 (NQF 0566): Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement – National Quality Strategy Domain: Effective Clinical Care

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
CLAIMS, REGISTRY

DESCRIPTION:
Percentage of patients aged 50 years and older with a diagnosis of age-related macular degeneration (AMD) or their caregiver(s) who were counseled within 12 months on the benefits and/or risks of the Age-Related Eye Disease Study (AREDS) formulation for preventing progression of AMD

INSTRUCTIONS:
This measure is to be reported a minimum of once per reporting period for AMD patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with AMD will submit this measure.

Measure Reporting via Claims:
ICD-10-CM diagnosis codes, CPT codes, and patient demographics are used to identify patients who are included in the measure’s denominator. CPT Category II codes are used to report the numerator of the measure.

When reporting the measure via claims, submit the appropriate ICD-10-CM diagnosis code, CPT codes, and the appropriate CPT Category II code with the modifier. The reporting modifier allowed for this measure is: 8P- reason not otherwise specified. There are no allowable performance exclusions for this measure. All measure-specific coding should be reported on the claim(s) representing the eligible encounter.

Measure Reporting via Registry:
ICD-10-CM diagnosis codes, CPT codes, and patient demographics are used to identify patients who are included in the measure’s denominator. The listed numerator options are used to report the numerator of the measure.

The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data. There are no allowable performance exclusions for this measure.

DENOMINATOR:
All patients aged 50 years and older with a diagnosis of AMD

Denominator Criteria (Eligible Cases):
Patients aged ≥ 50 years on date of encounter
AND
Diagnosis for AMD (ICD-10-CM): H35.30, H35.31, H35.32
AND
Patient encounter during the reporting period (CPT): 92002, 92004, 92012, 92014, 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99307, 99308, 99309, 99310, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337

NUMERATOR:
Patients with AMD or their caregiver(s) who were counseled within 12 months on the benefits and/or risks of the AREDS formulation for preventing progression of AMD

Definition:
Counseling – Documentation in the medical record should include a discussion of risk or benefits of the AREDS formulation. Counseling can be discussed with all patients with AMD, even those who do not meet
the criteria for the AREDS formulation, or other reasons why the patient would not meet criteria for AREDS formulation as outlined in the AREDS. The ophthalmologist or optometrist can explain why these supplements are not appropriate for their particular situation. Also, given the purported risks associated with antioxidant use, patients would be informed of the risks and benefits and make their choice based on valuation of vision loss vs. other risks. As such, the measure seeks to educate patients about overuse as well as appropriate use.

**NUMERATOR NOTE:** If patient is already receiving AREDS formulation, the assumption is that counseling about AREDS has already been performed.

**Numerator Quality-Data Coding Options for Reporting Satisfactorily:**

**ARED5 Counseling Performed**

**Performance Met: CPT II 4177F:** Counseling about the benefits and/or risks of the Age-Related Eye Disease Study (AREDS) formulation for preventing progression of age-related macular degeneration (AMD) provided to patient and/or caregiver(s)

**OR**

**ARED5 Counseling not Performed, Reason not Otherwise Specified**

Append a reporting modifier (8P) to CPT Category II code 4177F to report circumstances when the action described in the numerator is not performed and the reason is not otherwise specified.

**Performance Not Met: 4177F with 8P:** AREDS counseling not performed, reason not otherwise specified

**RATIONALE:**

1) Scientific basis for counseling regarding use of AREDS formulation for patients with AMD

Antioxidant vitamins and mineral supplements help to reduce the rate of progression to advanced AMD for those patients with intermediate or advanced AMD in one eye. From the same AREDS study, there is no evidence that the use of antioxidant vitamin and mineral supplements for patients with mild AMD alters the natural history of mild AMD.

At the same time, published meta-analyses have raised an issue as to the presence of an elevated mortality risk among patients taking elements similar to parts of the AREDS formulation (and elevated risk among smokers). As such, patients need to know of their individualized risk profile for taking the AREDS formula AND the potential benefits, so that they can make their OWN individual decision as to whether or not to take the AREDS formulation.

This indicator thus seeks to directly enhance the provider-patient relationship to apply the results of level 1 randomized controlled trials (RCTs) in a manner that accommodates the needs of each individual patient in a patient-centered manner, rather than a paternalistic approach of either recommending or withholding treatment.

2) Evidence of gap in care.

Antioxidant vitamins and mineral supplements help to reduce the rate of progression to advanced AMD for those patients with intermediate or advanced AMD in one eye. From the same AREDS study, there is no evidence that the use of antioxidant vitamin and mineral supplements for patients with mild AMD alters the natural history of mild AMD.

**CLINICAL RECOMMENDATION STATEMENTS:**
Patients with intermediate AMD or advanced AMD in one eye should be counseled on the use of antioxidant vitamin and mineral supplements as recommended in the Age-related Eye Disease Study (AREDS) reports. (A:I) (AAO, 2014)

**Antioxidant Vitamin and Mineral Supplements Used in the Age-Related Eye Disease Study 2**

<table>
<thead>
<tr>
<th>Supplement</th>
<th>Daily Dose*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin C</td>
<td>500 mg</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>400 IU</td>
</tr>
<tr>
<td>Lutein/zeaxanthin</td>
<td>10 mg/2 mg</td>
</tr>
<tr>
<td>Zinc oxide</td>
<td>80 mg or 25 mg</td>
</tr>
<tr>
<td>Cupric oxide</td>
<td>2 mg</td>
</tr>
</tbody>
</table>


* These doses are not those listed on the commercially available vitamin/mineral supplements because of a change in labeling rules by the U.S. Food and Drug Administration that specifies that the doses must reflect the amounts available at the end of the shelf life.

**COPYRIGHT:**
The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA), [on behalf of the Physician Consortium for Performance Improvement® (PCPI®)] or the American Academy of Ophthalmology (AAO). Neither the AMA, AAO, PCPI, nor its members shall be responsible for any use of the Measures.

The AMA’s and PCPI’s significant past efforts and contributions to the development and updating of the Measures is acknowledged. AAO is solely responsible for the review and enhancement (“Maintenance”) of the Measures as of May 15, 2014.

AAO encourages use of the Measures by other health care professionals, where appropriate.

**THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.**


Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, AAO, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measures specifications is copyright 2004-2015 American Medical Association.. All Rights Reserved.
2016 Claims/Registry Individual Measure Flow
PQRS #140 NQF #0566: Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement

Start

Denominator

Patient Age at Date of Service ≥ 50 Years

No

Not Included in Eligible Population/Denominator

No

Diagnosis of AMD as Listed in Denominator*

Yes

Encounter as Listed in Denominator* (1/1/2016 thru 12/31/2016)

Yes

Include in Eligible Population/Denominator

(8 patients)

Numerator

Age-Related Eye Disease Study (AREDS) Counseling Performed

Yes

Reporting Met + Performance Met 4177F or equivalent (4 patients)

No

AREDS Counseling Not Performed, Reason Not Specified

Yes

Reporting Met + Performance Not Met 4177-8P or equivalent (3 patients)

No

Reporting Not Met Quality-Data Code or equivalent not reported (1 patient)

SAMPLE CALCULATIONS:

Reporting Rate=

\[
\frac{\text{Performance Met (a=4 patients)}}{\text{Eligible Population / Denominator (d=8 patients)}} = \frac{4}{8} = 0.5 \times 100 = 50.00\%
\]

Performance Rate=

\[
\frac{\text{Performance Met (a=4 patients)}}{\text{Reporting Numerator (7 patients)}} = \frac{4}{7} = \frac{4}{7} \times 100 = 57.14\%
\]

*See the posted Measure Specification for specific coding and instructions to report this measure.

NOTE: Reporting Frequency – Patient-level

CPT® only copyright 2015 American Medical Association. All rights reserved.

The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.
2016 Claims/Registry Individual Measure Flow
PQRS #140 NQF #0566: Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement

Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in reporting this Individual Measure.

1. Start with Denominator

2. Check Patient Age:
   a. If Age greater than or equal to 50 years of age on Date of Service equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing.
   b. If Age greater than or equal to 50 years of age on Date of Service equals Yes during the measurement period, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis of AMD as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Diagnosis of AMD as Listed in the Denominator equals Yes, proceed to check Encounter Performed.

4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, include in the Eligible population.

5. Denominator Population:
   a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 patients in the sample calculation.

6. Start Numerator

7. Check Age-Related Eye Disease Study (AREDS) Counseling Performed:
   a. If Age-Related Eye Disease Study (AREDS) Counseling Performed equals Yes, include in Reporting Met and Performance Met.
   b. Reporting Met and Performance Met letter is represented in the Reporting Rate and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 4 patients in Sample Calculation.
   c. If Age-Related Eye Disease Study (AREDS) Counseling Performed equals No, proceed to AREDS Counseling Not Performed, Reason Not Specified

8. Check AREDS Counseling Not Performed, Reason Not Specified:
   a. If AREDS Counseling Not Performed, Reason Not Specified equals Yes, include in the Reporting Met and Performance Not Met.
b. Reporting Met and Performance Not Met letter is represented in the Reporting Rate in the Sample Calculation listed at the end of this document. Letter c equals 3 patients in the Sample Calculation.

c. If AREDS Counseling Not Performed, Reason Not Specified equals No, proceed to Reporting Not Met.

9. Check Reporting Not Met:

a. If Reporting Not Met equals No, Quality Data Code or equivalent not reported. 1 patient has been subtracted from the numerator in the sample calculation.

<table>
<thead>
<tr>
<th>SAMPLE CALCULATIONS:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reporting Rate=</td>
</tr>
<tr>
<td>Performance Met (a=4 patients) + Performance Not Met (c=3 patients) = 7 patients, = 87.50%</td>
</tr>
<tr>
<td>Eligible Population / Denominator (d=8 patients) = 8 patients</td>
</tr>
<tr>
<td>Performance Rate=</td>
</tr>
<tr>
<td>Performance Met (a=4 patients) = 4 patients, = 57.14%</td>
</tr>
<tr>
<td>Reporting Numerator (7 patients) = 7 patients</td>
</tr>
</tbody>
</table>

Version 10.0 CPT only copyright 2015 American Medical Association. All rights reserved.
11/17/2015 Page 6 of 6